Cynata Therapeutics (ASX:CYP) sacks its CEO to stretch A$1.5m past FY27

A A$600k R&D loan and a fee-waiving board are now the whole plan

Cynata Therapeutics (ASX:CYP) has done something companies rarely announce this bluntly. It has made every single employee redundant, including the CEO, the Chief Medical Officer and the Chief Business Officer, all effective today.

The board is now running the company itself. Dr Kilian Kelly, until this morning the CEO and Managing Director, stays on as a Non-Executive Director without pay. Dr Darryl Maher has resigned outright, and the remaining directors have waived their fees from 1 July 2026.

This is the endgame of the failed Phase 2 graft versus host disease trial that Cynata terminated on 17 June. With the lead clinical program gone, the board has stripped the company back to the minimum required to keep the lights on and protect the Cymerus intellectual property.

To fund that pause, Cynata has also drawn a A$600,000 loan against its anticipated FY26 R&D Tax Incentive rebate of roughly A$1.7 million. That takes proforma cash to A$1.5 million, with a further A$1 million plus expected once the rebate lands. Management now says the cash runway extends beyond the end of FY27.

The trial failed, so the company is dismantling itself to preserve optionality

The June termination of the GvHD trial removed the reason most retail holders owned this stock. Without that catalyst, sustaining a full biotech cost base would have burned through the balance sheet inside a year and forced a heavily dilutive raise at a broken share price.

The board has picked the other path. Fire everyone, terminate the Contract Research Organisation, shut down every outsourced activity that can be shut down, and keep only the spending required to hold onto the Cymerus patents and meet ASX and audit obligations.

Forecast FY27 cash burn now sits at around A$2.3 million. Of that, A$700,000 is employee termination payments and A$1.1 million is trial close-out costs, meaning ongoing corporate and IP maintenance runs at roughly A$500,000 a year. That is a genuinely skeletal operation.

The R&D loan is a bridge, not a lifeline

The A$600,000 facility matures on 30 September 2026 and must be repaid the moment the FY26 R&D rebate hits the bank account. It is secured against that rebate and a general security interest over Cynata’s assets.

It is worth noting that a commercial lender was still willing to write this loan against a company that has just terminated its lead trial and made its CEO redundant. The rebate itself is doing the heavy lifting on the credit decision.

The math from here is straightforward. Cynata ended FY26 with about A$0.9 million in cash. Add the loan, receive the rebate, repay the loan, and the company should sit somewhere near A$2.5 million heading into calendar 2027.

What Cymerus is actually worth to somebody else

The board says it is evaluating options for further development of the Cymerus platform. In plain English, Cynata is now a shell holding intellectual property and enough cash to keep the ASX listing alive while it looks for a buyer, licensee, or reverse takeover partner.

Our concern is that IP without a champion is a hard thing to monetise. The team that built and understood the platform has just been made redundant, and a part-time board is not a natural seller of complex biotech IP.

The Investors Takeaway for Cynata Therapeutics

For existing shareholders, Cynata has just morphed from a clinical-stage biotech into a cash-and-IP shell with an extended runway and no near-term catalysts. The upside case is a corporate transaction that assigns some value to Cymerus. The downside case is a slow drift toward eventual delisting or a nominal-value asset sale.

New investors should understand what they would actually be buying. Roughly A$2.5 million of net cash once the rebate lands, a listed shell with tightly controlled costs, and a patent estate whose commercial value now depends on a part-time board finding the right counterparty.

More coverage of ASX-listed biotech names is available at stocksdownunder. The next real update from Cynata will be whatever the board can announce on the strategic review, and until then this is a story about survival, not science.